Previous studies have reported that anti-Ro52 antibodies significantly correlated with ILD in DM, juvenile myositis, primary Sjögren syndrome, and connective tissue diseases, suggesting anti-Ro52 is an intended risk factor for ILD (21–25). Here, TRIM21 is linked to interstitial lung disease.